Literature DB >> 12562030

Measurement of adherence to antiretroviral medications.

David L Paterson1, Brian Potoski, Blair Capitano.   

Abstract

Measurement of adherence may be important in determining why patients fail antiretroviral therapy. Although patient self-report is by far the most frequently used means of assessing adherence, it overestimates adherence. However, patients who state they are nonadherent almost always are. The pill identification test is a recently described tool that may be useful in clinical practice. The best methods of adherence measurement are pill counts and electronic monitoring. Pill counts suffer from inability to record the time of consumption of therapy. Electronic monitoring enables timing of pill consumption and is the closest to a gold standard for measuring adherence. However, this is only the case if patients are carefully instructed in how to use the device, e.g., not to remove extra doses from their pill bottle. A composite adherence score has been developed that uses electronic monitoring, pill counts, and patient self-report. The authors believe that careful measurement of adherence is essential in the assessment of a patient failing to respond to antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12562030     DOI: 10.1097/00126334-200212153-00003

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  43 in total

Review 1.  Measuring adherence to highly active antiretroviral therapy: implications for research and practice.

Authors:  Thomas Kerr; John Walsh; Elisa Lloyd-Smith; Evan Wood
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

2.  Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues.

Authors:  Cynthia R Pearson; Jane M Simoni; Peter Hoff; Ann E Kurth; Diane P Martin
Journal:  AIDS Behav       Date:  2007-03

Review 3.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

Review 4.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

5.  Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy.

Authors:  Duncan Smith-Rohrberg Maru; R Douglas Bruce; Mary Walton; Jo Anne Mezger; Sandra A Springer; David Shield; Frederick L Altice
Journal:  AIDS Behav       Date:  2007-12-18

6.  Discrepancies between self-report and objective measures for stimulant drug use in HIV: cognitive, medication adherence and psychological correlates.

Authors:  M J Reinhard; C H Hinkin; T R Barclay; A J Levine; S Marion; S A Castellon; D Longshore; T Newton; R S Durvasula; M N Lam; H Myers
Journal:  Addict Behav       Date:  2007-04-14       Impact factor: 3.913

7.  Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics.

Authors:  Laetitia Comté; Bernard Vrijens; Eric Tousset; Paul Gérard; John Urquhart
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.745

8.  Unannounced telephone-based pill counts: a valid and feasible method for monitoring adherence.

Authors:  R Fredericksen; B J Feldman; T Brown; S Schmidt; P K Crane; R D Harrington; S Dhanireddy; J McReynolds; W B Lober; D R Bangsberg; M M Kitahata; Heidi M Crane
Journal:  AIDS Behav       Date:  2014-12

9.  HIV Medication Adherence and Substance Use: The Smartest Women's Project.

Authors:  Eliot Lopez; Deborah L Jones; Mary Ishii; Jonathan N Tobin; Stephen M Weiss
Journal:  Am J Infect Dis       Date:  2007

10.  Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects.

Authors:  Jessica E Haberer; Adrian Cook; A Sarah Walker; Marjorie Ngambi; Alex Ferrier; Veronica Mulenga; Cissy Kityo; Margaret Thomason; Desiree Kabamba; Chifumbe Chintu; Diana M Gibb; David R Bangsberg
Journal:  PLoS One       Date:  2011-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.